Pediatric thyroid side effects of immune checkpoint inhibitors
-
Published:2024-09
Issue:9
Volume:35
Page:765-768
-
ISSN:1043-2760
-
Container-title:Trends in Endocrinology & Metabolism
-
language:en
-
Short-container-title:Trends in Endocrinology & Metabolism
Author:
Morgante CesareORCID,
Fierabracci AlessandraORCID,
Grossi ArmandoORCID
Reference15 articles.
1. Immune-checkpoint inhibitors: long-term implications of toxicity;Johnson;Nat. Rev. Clin. Oncol.,2022
2. Phase 1 clinical trial of durvalumab in children with solid and central nervous system tumors;Mascarenhas;J. Clin. Oncol.,2022
3. A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children’s Oncology Group Study ADVL1412;Davis;Clin. Cancer Res.,2022
4. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial;Geoerger;Lancet Oncol.,2020
5. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study;Geoerger;Lancet Oncol.,2020